Camrelizumab with chemo before surgery versus chemo-radiation
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 3 trial compares two ways of treating resectable esophageal squamous cell cancer: (1) camrelizumab plus chemotherapy before surgery versus (2) chemo-radiation. It aims to see whether adding camrelizumab before surgery can improve outcomes for people who are planned to have their tumor surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your biopsy must show esophageal squamous cell carcinoma (a specific type of esophageal cancer).
- You have not had chemo, radiation, or other cancer medicines for esophageal cancer before.
- Your cancer must be “resectable,” meaning doctors think it can be removed with surgery, and staging must fit T1b-3 N1-3 M0 or T3 N0 M0 (per AJCC 8th edition).
- You must be between 18 and 75 years old, with an ECOG health/activity score of 0 to 1.
- You need to be able to undergo R0 surgery (no visible cancer left behind), and you must be planned for surgery after the “neoadjuvant” (before-surgery) treatment is done.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
This trial tests a combination of immunotherapy (camrelizumab), chemotherapy, and a targeted drug (ivarmacitinib) before surgery for esophageal cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial compares adding immunotherapy to standard chemo-radiation before surgery for locally advanced, operable esophageal squamous cell cancer. It aims to improve how well the tumor responds and whether patients do better after surgery.
This trial tests whether giving chemotherapy combined with immunotherapy before surgery works better than the standard chemoradiation for esophageal cancer that can be removed. It may help reduce tumor size and improve outcomes.
This trial tests whether giving pembrolizumab (an immune therapy) plus chemotherapy before surgery can improve outcomes for people with locally advanced, operable esophageal squamous cell carcinoma. It may help shrink the tumor and improve the chance of successful surgery.
Hear when a new Resectable Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.